Results 131 to 140 of about 2,251,685 (405)

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma

Nature, 2023
Jing Hu, Francisco J. Sánchez-Rivera, Zhenghan Wang, Gabriela N. Johnson, Yu-jui Ho, K. Ganesh, S. Umeda, Siting Gan, Adriana M. Mujal, R. Delconte, Jessica P. Hampton, Huiyong Zhao, Sanjay V. Kottapalli, E. de Stanchina, C. Iacobuzio-Donahue, D. Pe’er, S. Lowe, Joseph C. Sun, J. Massagué   +18 more
semanticscholar   +1 more source

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

Journal of Pathology, 2019
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC).
Thijs S. Stutvoet, A. Kol, E. D. de Vries, M. de Bruyn, R. Fehrmann, A. T. V. Terwisscha van Scheltinga, S. de Jong   +6 more
semanticscholar   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Identification of integrin drug targets for 17 solid tumor types. [PDF]

, 2018
Integrins are contributors to remodeling of the extracellular matrix and cell migration. Integrins participate in the assembly of the actin cytoskeleton, regulate growth factor signaling pathways, cell proliferation, and control cell motility.
Arun, Adith S, Lam, Kit S, Tepper, Clifford G   +2 more
core   +1 more source

LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway

Journal of experimental & clinical cancer research : CR, 2019
Brain metastasis (BM) is associated with poor prognosis, recurrence, and death in patients with non-small cell lung cancer (NSCLC). Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been reported to be involved in the progression, metastasis and ...
C. Wei, Xiaomin Dong, Hui Lu, F. Tong, Lingjuan Chen, Ruiguang Zhang, Ji-hua Dong, Yu Hu, Gang Wu, Xiaorong Dong   +9 more
semanticscholar   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

FEBS Open Bio, EarlyView.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava, Anoop Saraya, Deepak Gunjan, Rinu Sharma   +3 more
wiley   +1 more source

VASN promotes the aggressive phenotype in ARID1A-deficient lung adenocarcinoma

BMC Cancer
Loss of ARID1A has been reported to drive the progression of lung adenocarcinoma, yet the underlying mechanism remains elusive. In this study, we performed secretome analysis to identify the key secreted proteins regulating lung adenocarcinoma ...
Dan-ni Wu, Kang-liang Zhang, Rui-heng Chen, Wen-sheng Ye, Chong Zheng, Yuan-liang Zheng, Xiao-dan Zhao, Ri-sheng Huang   +7 more
doaj   +1 more source

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]

, 2019
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner, AB D’Assoro, AJ Lee, AN Hata, Andrei Goga, Andrew D. Simmons, Angel Ku, AS Nikonova, Ashley Maynard, B Melichar, CA Eberlein, CK Lee, CM Blakely, CM Blakely, Collin M. Blakely, D Ercan, DB Costa, F Varghese, Frank McCormick, Golzar Hemmati, Gregor Krings, Hayley J. Donnella, Henry J. Haringsma, J Chen, J Fu, Jacqueline Galeas, JJ Chabon, Jonathan Kuhn, Julia Rohrberg, Julia Rotow, K Shien, Khyati N. Shah, KS Thress, L Li, Liliane Robillard, LV Sequist, LV Sequist, M Moustafa-Kamal, M Ramirez, Maria M. Martins, MJ Niederst, MS Cragg, MW Karaman, OJ Gruss, PA Jänne, R Rosell, RA Burrell, Roma Bhatt, S Anand, S Stewart, Sophie Dumont, Sourav Bandyopadhyay, SV Sharma, Swati Kaushik, T Sharifnia, TC Chou, TG Bivona, TG Bivona, Thomas C. Harding, TM Kim, Trever G. Bivona, V Bavetsias, Victor Olivas, Victoria E. Wang, Y Zhou, Z Piotrowska, Z Yang   +66 more
core   +1 more source

Metastatic Lung Adenocarcinoma [PDF]

Ophthalmology, 2017
Anton M, Kolomeyer, Alexander J, Brucker, Joan M, O'Brien   +2 more
openaire   +2 more sources

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma.

Cancer Discovery, 2019
Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responses-such as ...
Fei Li, Qingyuan Huang, T. Luster, Hai Hu, Hua Zhang, Wai-Lung Ng, A. Khodadadi-Jamayran, Wei Wang, Ting Chen, Jiehui Deng, M. Ranieri, Zhaoyuan Fang, V. Pyon, C. Dowling, Ece Bagdatlioglu, C. Almonte, K. Labbe, Heather Silver, Alexandra R. Rabin, Kandarp Jani, A. Tsirigos, T. Papagiannakopoulos, P. Hammerman, V. Velcheti, G. Freeman, J. Qi, G. Miller, Kwok-kin Wong   +27 more
semanticscholar   +1 more source